Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume

British Journal of Clinical Pharmacology

Volumn 78, Issue 6, 2014, Pages 1291-1297

  Edeki, Timi ^a   Kujacic, Mirjana ^b   Broadhurst, Helen ^a   Li, Jianguo ^a   Sunzel, Maria ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Bacterial infections; Ceftaroline fosamil; Infusion parameters; Pharmacokinetics; Safety

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; DRUG METABOLITE; PLACEBO; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE DISORDER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; HYPERSALIVATION; INFUSION RELATED REACTION; INFUSION SITE PHLEBITIS; INFUSION SITE THROMBOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE DRUG DOSE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL INFUSION PHLEBITIS SCALE; VOLUME OF DISTRIBUTION; VOMITING; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE;

EID: 84918808336     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12465     Document Type: Article

References (23)

1. AstraZeneca AB. ZINFORO™ 600 mg powder for concentrate for solution for infusion: summary of product characteristics. September 2012. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002252/WC500132586.pdf (last accessed 23 October 2013).
2. Forest Pharmaceuticals Inc. Teflaro® (ceftaroline fosamil) injection for intravenous (IV) use: US prescribing information. July 2013. Available at http://www.frx.com/pi/Teflaro-pi.pdf (last accessed 23 October 2013).
3. Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 2013; 73: 1067-94.
4. Lodise TP, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012; 72: 1473-93.
5. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.
6. File TM Jr., Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
7. Nair V, Niederman MS, Masani N, Fishbane S. Hyponatremia in community-acquired pneumonia. Am J Nephrol 2007; 27: 184-90.
8. Pereira G, Guevara M, Fagundes C, Sola E, Rodriguez E, Fernandez J, Pavesi M, Arroyo V, Gines P. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol 2012; 56: 1040-6.
9. Schuster L, Nunez DE. Using clinical pathways to aid in the diagnosis of necrotizing soft tissue infections synthesis of evidence. Worldviews Evid Based Nurs 2012; 9: 88-99.
10. Goh KP. Management of hyponatremia. Am Fam Physician 2004; 69: 2387-94.
11. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010; 170: 294-302.
12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
13. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006; 48: S1-S322.
14. Ge Y, Redman R, Floren L, Liao S, Wikler M. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects [poster A-1936]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
15. Ge Y, Redman R, Floren L, Liao S, Wikler M. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions [poster A-1937]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
16. Ge Y, Thye D, Liao S, Talbot GH. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI) [poster A-1939]. Presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 27-30, 2006; San Francisco, CA.
17. Yang L, Li H, Sunzel M, Xu P, Edeki T, Li J. Pharmacokinetics (PK) and safety of single and multiple intravenous (IV) infusions of ceftaroline fosamil in healthy Chinese subjects. Int J Antimicrob Agents 2013; 42: S78.
18. Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. J Clin Pharmacol 2014; 54: 742-52.
19. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: 3612-6.
20. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (Suppl. 4): iv67-iv71.
21. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with communityacquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 3): iii53-iii59.
22. National Institute for Health and Care Excellence. Infection: prevention and control of healthcare-associated infections in primary and community care. Clinical guidelines, CG139. March 2012. Available at http://guidance.nice.org.uk/CG139 (last accessed 17 October 2013).
23. Centers for Disease Control and Prevention. 2011 Guidelines for the Prevention of Intravascular Catheter-Related Infections. 2011. Available at http://www.cdc.gov/hicpac/BSI/01-BSI-guidelines-2011.html (last accessed 31 October 2013).